Revolution Medicines, Inc.
RVMD · Nasdaq
- $203.77
- $43.96B
- Open
- —
- —
- $200.17 - $206.54
- $42.18 - $224.31
- —
- —
- 1.27M
About Revolution Medicines, Inc.
Revolution Medicines is a biotechnology company developing cancer medicines. The supplied evidence specifically identifies a promising cancer drug in development, but does not name marketed products, clinical-stage programs, operating segments, or commercial partners. The company therefore has no reported commercial revenue in the supplied financials: FY2025 revenue is $0.0 billion, compared with a $1.1 billion net loss; FY2024 revenue is also $0.0 billion and the net loss is $0.6 billion. Its present scale is consequently defined by research and development activity and substantial losses rather than product sales or an established customer base.
Notable Price Movement
- Aug 3-7$205.159.40%
RVMD rose $9.60, or 5.22%, from $183.86 to $193.46 over the reported week. The supplied evidence identifies no company-specific announcement or operating update to explain the gain. Trading was volatile: the stock slipped to $180.92 on July 29, surged to $192.17 on July 30, gave back part of that advance to $187.53 on July 31 and $182.45 on August 3, then rebounded $11.01 on August 4. Investor attention around Stanley Druckenmiller’s new stake and favorable commentary about Revolution Medicines’ cancer-drug pipeline may have supported sentiment, but the evidence does not establish that either item occurred during this week. No broader market driver is supplied.
